Autoimmune Gastrointestinal Dysmotility (AGID) Evaluation

Clinical Utility of AGID Evaluation

April 2012

So what are the appropriate clinical circumstances to do the autoimmune gastrointestinal dysmotility serological evaluation?  There are 5 specific uses for this testing. Firstly, this could be used for investigating acquired idiopathic gastrointestinal dysmotility to see if an idiopathic autoimmune or paraneoplastic basis can be established for this. This can then help direct treatment. If 1 or more of the antibodies described were detected, this may increase the clinician’s confidence that a trial of immunosuppression is warranted. Thirdly, the antibody profile detected can help predict the cancer type. Fourthly, this testing can be used to investigate gastrointestinal dysmotility occurring during cancer therapy that was not explainable by recurrent cancer or metastasis.

< Previous Slide

Clinical Utility of AGID Evaluation

Next Slide >

 

Jump to section:

• Introduction
• New Profile
• AGID
• Symptoms
• AGID¹
• AGID^1,2
• AGID: Laboratory Findings
• AGID: Antibody Evaluation
• Ganglionic Acetylcholine Receptor (AChR) Autoantibody^3,4
• Ganglionic AChR Autoantibody
• AGID Antibody Profile
• AGIDE/89886 Algorithm
• AGIDE/89886 Algorithm
• AGIDE/89886 Algorithm
• AGIDE/89886 Algorithm
• Clinical Utility of AGID Evaluation
• Clinical Utility of AGID Evaluation
• Summary
• References
• Questions